The present invention relates to a film-coated swallowable tablet comprising eltrombopag bis(monoethanolamine) and pharmaceutically acceptable excipients comprising calcium silicate as diluent. The invention further relates to the use of said tablet as a medicament, particularly in the treatment of immune thrombocytopenia (ITP), thrombocytopenia in patients with chronic hepatitis C virus (HCV) and severe aplastic anaemia (SAA).

The present disclosure provides use of a combination of acyclovir and dexamethasone (DXMT) in preparation of a drug for treating Alzheimer's disease (AD); where the use includes all symptoms of a patient with the AD, especially following symptoms: cognitive impairment and neuroinflammation. Combination of the acyclovir and the DXMT has a synergistic effect, to exert anti-inflammatory and immunoregulation effects to achieve a therapeutic effect.

Amlodipine mesylate monohydrate, a preparation method therefor and a use thereof. The described amlodipine mesylate monohydrate has high purity, has good fluidity and compressibility, and is suitable for direct tableting processing by a high-speed tablet press.

Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

Viral epidemic infections due to influenza, or coronaviruses, particularly influenza A and SARS-CoV-1 and -2 virus cause significant morbidity and mortality. The significant mutation rate of this group of viruses renders existing vaccines or antiviral drugs often useless, creating a need for broad acting, viral DNA or RNA sequence independent antiviral drugs. This invention describes the repurposing of methylene blue and riboflavin, two FDA approved drugs with an excellent safety profile. Using a virus neutralization assay of H1N1 Influenza A and SARS-CoV-2, the significant viricidal activity of both drugs at pharmacological dose and under physiological conditions is demonstrated. In vivo prophylactic and therapeutic use of the drugs for anti-viral application in an animal model is described.

The present disclosure relates, in general, to: (a) solid pharmaceutical dosage forms comprising acalabrutinib maleate; (b) methods of using such pharmaceutical dosage forms to treat B-cell malignancies and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods.

Methods and formulations for treating and preventing LONG COVID sequelae are provided. An example method treats loss of smell and taste from SARS-CoV-2 infection, including assessing the patient, administering a composition with dosage between 1750-3600 mg per day, wherein the composition comprises a mixture of at least a withanolide-A, a boswellic acid, a [6]-gingerol, and a curcuminoid. Another example method treats memory loss or brain fog from SARS-CoV-2 infection, including assessing the patient, and administering a regenerative and neuroprotective composition comprising a mixture of withanoside VI, withanolide A, a Boswellia serrata plant, a Zingiber officinale rhizome, and a Curcuma longa rhizome. The compositions were found effective, achieving statistical significance in a multi-center, randomized, double-blind, placebo-controlled phase III clinical trial.

Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor nilotinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer. In particular, the present disclosure provides a pharmaceutical composition in the form of an orally disintegrating tablet. In some embodiments, the pharmaceutical compositions can be administered without regard to food consumption. In other embodiments, the pharmaceutical compositions can be administered at a significantly lower dose as compared to a commercially available immediate-release nilotinib formulation, while providing a comparable therapeutic effect.

The present invention relates to a novel compound that has antiviral activity, in particular, inhibitory activity against the integrase of the human immunodeficiency virus (HIV).

The subject of this invention is a novel annelated 9-hydroxy-1,8-dioxo-1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine-7-carboxamide of general formula 1 or 2, or any stereoisomer, any pharmaceutically acceptable salt, any solvate, or any crystalline or polycrystalline form thereof

##STR00001## wherein ring A.sup.1 is an optionally methyl-substituted 5-7 membered saturated heterocycle or heterobicycle; ring A.sup.2 is a 5-6 membered optionally methyl-substituted saturated or partially saturated monocyclic heterocycle; ring A.sup.3 is a 5-6 membered monocyclic saturated cycloalkane or tetrahydro-2H-pyran; R is a 5-7 membered optionally substituted with one, two, or three optionally identical substituents monocyclic or bicyclic heterocyclic radical comprising 1-4 heteroatoms selected from the series O, S, and N except (2S,5R,13aS)-8-hydroxy-7,9-dioxo-N-{[3-(trifluoromethyl)-pyridin-2-yl]methyl}-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopurido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide (formula A4) and (1R,4S,12aR)-N-[(3,5-difluoropyridin-2-yl)methyl]-7-hydroxy-6,8-dioxo-1,2,3,4,6,8,12,12a-octahydro-1,4-methanodipyrido[1,2-a:1′,2′-d]pyrazine-9-carboxamide (formula A5).

The present invention relates to an amorphous solid dispersion comprising ABX464 and at least one pharmaceutically acceptable carrier. The present invention also concerns a pharmaceutical composition comprising said ASD, processes for their preparation, an ASD obtainable by specific processes, their use as a medicament and more particularly their use in the treatment and/or prevention of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.